Global Hypertrophic Cardiomyopathy Therapeutics Market to reach US$1.4 bn by 202311 Jan 2016
Transparency Market Research has published a new market report titled, “Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023.” According to the report, the global hypertrophic cardiomyopathy therapeutics market was valued at US$1.2 bn in 2014 and is expected to expand at a CAGR of 1.4% from 2015 to 2023 to reach US$1.4 bn by 2023.
Browse Full Report With TOC:- http://www.transparencymarketresearch.com/hypertrophic-cardiomyopathy-therapeutics-market.html
The report provides detailed analysis of current and emerging drugs for hypertrophic cardiomyopathy (HCM), bifurcating them based on type of drug class. Drugs have been analyzed by segments such as beta adrenergic blocking agents, calcium channel blocker, antiarrhythmic agents, and anticoagulants. Calcium channel blockers was the largest segment of the global hypertrophic cardiomyopathy therapeutics market in 2014. The segment dominated the market due to high price of calcium channel blockers in comparison to other drugs.
The beta adrenergic blocking agent segment is projected to expand at the second highest CAGR during the forecast period from 2015 to 2023, as it is the first choice of treatment for obstructive and non-obstructive HCM. The antiarrhythmic and anticoagulants drug segments held the third and fourth largest shares of the global market in terms of revenue in 2014. However, rising technological upgrade of devices such as defibrillators and pacemakers could restraint market growth. The hypertrophic cardiomyopathy therapeutics market is likely to be driven by increase in sedentary lifestyle among the young population and rise in obese population.
Sanofi S.A. and Pfizer, Inc. dominated the global hypertrophic cardiomyopathy therapeutics market in 2014. AstraZeneca plc, Concordia Healthcare Corp., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are the other major companies operating in the global hypertrophic cardiomyopathy therapeutics market.
The global hypertrophic cardiomyopathy therapeutics market has been segmented as follows:
Global Hypertrophic Cardiomyopathy Therapeutics Market, by Drug Class
Beta Adrenergic Blocking Agents
Calcium Channel Blocker
Request For Sample Report:- http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7553
Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
Transparency Market Research
90 State Street,
Albany NY - 12207